- |||||||||| Review, Journal: Anabolic Resistance of Muscle Protein Turnover Comes in Various Shapes and Sizes. (Pubmed Central) - May 25, 2021
Namely, we discuss the fact that anabolic resistance exists as a dimmer switch, capable of varying from higher to lower levels of resistance, to the main anabolic stimuli of feeding and exercise depending on the population. Moreover, we review the evidence on whether increased physical activity and targeted exercise can be leveraged to restore the sensitivity of skeletal muscle tissue to dietary amino acids regardless of the population.
- |||||||||| Review, Journal: Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. (Pubmed Central) - May 22, 2021
In this perspective review, we discuss key pathophysiological processes driving sarcopenia in NAFLD: anabolic resistance, insulin resistance, metabolic inflexibility and systemic inflammation. Interventions that modify muscle quantity (mass), muscle quality (fat), and physical function by simultaneously engaging multiple targets and pathways implicated in muscle-liver crosstalk may be required to address the multifactorial pathogenesis of NAFLD/NASH and provide effective and durable therapies.
- |||||||||| Clinical, Journal: Approach to Obesity in the Elderly. (Pubmed Central) - May 22, 2021
Risk-benefit issues should be considered with extreme care and disclosed to candidates. The selection process requires good presurgical functional status, individualized consideration of the sequels of obesity and reliance on centers which are highly experienced in the surgical procedure as well as short and long term subsequent comprehensive care and support.
- |||||||||| [VIRTUAL] SARCOPENIA RATE IN COVID-19 SURVIVORS () - May 21, 2021 - Abstract #EULAR2021EULAR_3470;
We here highlighted a sarcopenia prevalence at 3 and 6 months following a hospitalization for COVID-19 of 13% and 3% respectively, occurring mainly in patients with comorbidities. Sarcopenia was not associated to worse cardio-pulmonary results in comparison with non-sarcopenic patients.
- |||||||||| [VIRTUAL] DIAGNOSTIC VALUE OF MUSCLE STRENGTH TESTS FOR THE DIAGNOSIS OF SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_3134;
This method shows that patients with obesity have a significantly reduced muscle mass compared with normal weight or overweight subjects. Muscle strength tests proposed by the European Working Group on Sarcopenia in Older People have a low specificity, diagnostic accuracy and positive predictive values for detecting SP in RA patients, which requires the development of other methods of the first step of diagnosis of SP in RA patients.
- |||||||||| temozolomide / Generic mfg.
Clinical, Journal: Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. (Pubmed Central) - May 21, 2021 • We appraised the correlation among TMT and survival, sex, age at surgery, and performance status, measured on brain MRIs of patients affected by glioblastoma at diagnosis. • TMT did not show any significant correlation with prognosis, age at surgery, or performance status, and its usefulness might be restricted only to patients with brain metastases and recurrent or treated glioblastoma.
- |||||||||| Review, Journal: Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview. (Pubmed Central) - May 21, 2021
There is evolving research in many chronic inflammatory states, such as chronic liver disease and rheumatoid arthritis, whereby interventions have begun to be developed to counteract sarcopenia. The purpose of this review is to evaluate the current literature regarding the impact of sarcopenia in the management of IBD, from mechanistic drivers through to assessment and management.
- |||||||||| Clinical, Review, Journal: Body Composition Methods in Adults with Type 2 Diabetes or at Risk for T2D: a Clinical Review. (Pubmed Central) - May 21, 2021
Review findings indicate that these methods were capable of identifying clinically relevant T2D disease-related complications such as sarcopenia and T2D risk factors such as obesity or regional adiposity. However, estimates were often sex and race/ethnicity specific warranting cross-validation of these methods in broader populations with T2D or risk for T2D prior to clinical implementation.
- |||||||||| Biomarker, Review, Journal: MRI-Derived Biomarkers Related to Sarcopenia: A Systematic Review. (Pubmed Central) - May 20, 2021
Future studies should test and compare the performance of proposed MRI biomarkers for sarcopenia characterization and quantification using a standardized experimental setup. 1 Technical Efficacy Stage: 2.
- |||||||||| Review, Journal: Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments. (Pubmed Central) - May 20, 2021
Healthy diet and physical activity are beneficial to both sarcopenic obesity and diabetes, but there are only recommended drugs for diabetes. This review consolidates and discusses the latest research in pathogenesis, diagnosis, and treatments of diabetes and sarcopenic obesity.
|